- Abstract:
-
Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block. Single-agent enasidenib (AG-221/CC-90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a ph...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
- Publisher:
- American Society of Hematology Publisher's website
- Journal:
- Blood Journal website
- Volume:
- 130
- Issue:
- 6
- Pages:
- 732-741
- Publication date:
- 2017-08-10
- Acceptance date:
- 2017-05-28
- DOI:
- EISSN:
-
1528-0020
- ISSN:
-
0006-4971
- Pubs id:
-
pubs:700685
- URN:
-
uri:fe1cab64-86fd-40ed-9bbe-700d65bd7794
- UUID:
-
uuid:fe1cab64-86fd-40ed-9bbe-700d65bd7794
- Local pid:
- pubs:700685
- Language:
- English
- Copyright holder:
- American Society of Hematology
- Copyright date:
- 2017
- Notes:
- © 2017 by The American Society of Hematology. This is the author accepted manuscript following peer review version of the article. The final version is available online from American Society of Hematology at: 10.1182/blood-2017-04-779447
Journal article
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Actions
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record